Vietnam's National Hygiene and Epidemiology Institute has conducted the first large-scale human trial of a vaccine against the avian influenza virus (H5N1). A report from the Vietnam News stated that 30 healthy volunteers from the Military Medical Institute, Hanoi, were given the locally-developed drug, which has been in development for four years. A further 240-person trial is scheduled in June, with a launch date for the product in 2009, priced at $2 per dose. The Vaccine and Biotechnology Products Company No 1 developed the vaccine from monkey kidney cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze